Related Experiment Video

Updated: Aug 23, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Genetics of the variable expression of CYP3A in humans

Leszek Wojnowski1

  • 1Department of Clinical Pharmacology, Johannes Gutenberg University, D-55101 Mainz, Germany. wojnowski@uni-mainz.de

Therapeutic Drug Monitoring
|July 2, 2004
PubMed

Insights

Genetic and environmental factors influence Cytochrome P450 3A (CYP3A) activity, impacting drug metabolism and cancer risk. New genetic markers for CYP3A5 and CYP3A7 are advancing personalized medicine by enabling isozyme-specific activity assessment.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Molecular Biology

Background:

  • Cytochrome P450 3A (CYP3A) isozymes are crucial for metabolizing approximately 50% of prescription drugs, steroid hormones, toxins, and carcinogens.
  • CYP3A expression levels significantly influence drug efficacy, safety, and individual susceptibility to cancers.
  • Variability in CYP3A expression arises from complex genetic and environmental interactions.

Purpose of the Study:

  • To review recent advancements in the genomics and regulation of CYP3A.
  • To highlight the potential of newly identified genetic markers for predicting individual CYP3A activity.
  • To discuss the implications for personalized medicine and improved drug therapies.

Main Methods:

  • Review of recent scientific literature on CYP3A genomics and regulation.
  • Analysis of newly described genetic polymorphisms in CYP3A5 and CYP3A7.
  • Discussion of the development of isozyme-specific activity markers.

Main Results:

  • Recent progress in understanding CYP3A gene regulation and expression has been summarized.
  • Identification of specific genetic markers for CYP3A5 and CYP3A7 polymorphisms has been achieved.
  • These markers are expected to aid in developing isozyme-specific activity predictors for CYP3A4 and other CYP3A family members.

Conclusions:

  • The development of predictive markers for individual CYP3A activity is crucial for personalized drug dosing.
  • Recent discoveries in CYP3A5 and CYP3A7 genetics represent a significant step towards this goal.
  • Further research into isozyme-specific markers will enhance therapeutic strategies involving CYP3A substrates.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...